RUBY
Income statement / Annual
Last year (2022), Rubius Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Rubius Therapeutics, Inc.'s net income was -$230.86 M.
See Rubius Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$96.41 M
|
$141.59 M
|
$116.11 M
|
$112.42 M
|
$51.77 M
|
$21.23 M
|
$8.40 M
|
| General & Administrative
Expenses |
$30.84 M
|
$53.03 M
|
$50.34 M
|
$57.18 M
|
$39.89 M
|
$22.04 M
|
$2.45 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$30.84 M
|
$53.03 M
|
$50.34 M
|
$57.18 M
|
$39.89 M
|
$22.04 M
|
$2.45 M
|
| Other Expenses |
$1.82 M |
-$1.93 M |
-$1.28 M |
$6.14 M |
$2.47 M |
-$785,000.00 |
-$16,000.00 |
| Operating Expenses |
$127.25 M |
$194.62 M |
$166.45 M |
$169.60 M |
$91.66 M |
$43.26 M |
$10.85 M |
| Cost And Expenses |
$127.25 M |
$194.62 M |
$166.45 M |
$169.60 M |
$91.66 M |
$43.26 M |
$10.85 M |
| Interest Income |
$819,000.00 |
$91,000.00 |
$1.76 M |
$7.99 M |
$5.12 M |
$511,000.00 |
-$16,000.00 |
| Interest Expense |
$3.86 M |
$6.43 M |
$4.19 M |
$2.59 M |
$464,000.00 |
$309,000.00 |
$149,000.00 |
| Depreciation &
Amortization |
$6.25 M
|
$7.72 M
|
$5.69 M
|
$3.00 M
|
$1.26 M
|
$447,000.00
|
$118,000.00
|
| EBITDA |
-$118.35 M
|
-$194.62 M
|
-$166.45 M
|
-$169.60 M
|
-$91.66 M
|
-$42.31 M
|
-$10.75 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1.22 M
|
-$1.93 M
|
-$1.28 M
|
$6.14 M
|
$2.47 M
|
-$583,000.00
|
-$164,000.00
|
| Income Before Tax |
-$179.67 M |
-$196.55 M |
-$167.73 M |
-$163.46 M |
-$89.20 M |
-$43.85 M |
-$11.02 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$51.20 M |
-$7.72 M |
-$5.69 M |
-$3.00 M |
$2.93 M |
$309,000.00 |
$133,000.00 |
| Net Income |
-$230.86 M |
-$188.82 M |
-$162.04 M |
-$160.46 M |
-$89.20 M |
-$43.85 M |
-$11.02 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.56 |
-2.15 |
-2.01 |
-2.04 |
-2.27 |
-5.13 |
-1.29 |
| EPS Diluted |
-2.56 |
-2.15 |
-2.01 |
-2.04 |
-2.27 |
-5.13 |
-1.29 |
| Weighted Average Shares
Out |
$90.31 M
|
$87.95 M
|
$80.62 M
|
$78.69 M
|
$39.29 M
|
$8.54 M
|
$8.54 M
|
| Weighted Average Shares
Out Diluted |
$90.31 M
|
$87.95 M
|
$80.62 M
|
$78.69 M
|
$39.29 M
|
$8.54 M
|
$8.54 M
|
| Link |
|
|
|
|
|
|
|
